Clinical Trial Update: Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma [Phase 2]

View source ↗

Summary

Avelumab was studied in a Phase 2 trial for relapsed or refractory peripheral T-cell lymphoma, and the results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• BAVENCIO (AVELUMAB)

Snippet

Sponsor: University of Birmingham | Conditions: T-Cell Lymphoma Relapsed, T-Cell Lymphoma Refractory | Phase 2 | Status: COMPLETED | Results posted: 2024-07-16